Skip to main content

Table 2 Summary of neoadjuvant therapy

From: Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study

Treatment regimens

COPD

Non-COPD

Pembrolizumab + Paclitaxel liposomes + platin

10

19

Pembrolizumab + nab‑paclitaxel + platin

1

3

Pembrolizumab + Pemetrexed + platin

2

0

Nivolumab + Paclitaxel liposome + platin

2

0

Tirellizumab + Paclitaxel liposome + platin

5

8

Toripalimab +  + Paclitaxel liposome + platin

1

1

Sintilimab + Paclitaxel liposome + platin

3

2

Sintilimab + Pemetrexed + platin

0

1

Camrelizumab + Pemetrexed + platin

1

4

Durvalumab + Paclitaxel liposome + platin

4

2

Durvalumab + Pemetrexed + platin

0

2

Atezolizumab + nab‑paclitaxel + platin

1

1

Atezolizumab + Pemetrexed + platin

0

1